Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Tevogen Bio Holdings (Nasdaq: TVGN) has received an international patent publication from WIPO for its AI technology that predicts immunologically active peptides. The patent (WO 2025/129197) covers Tevogen.AI's machine learning technology, powered by Microsoft and Databricks, designed to identify peptides with strong immune system interactions.
The technology aims to overcome traditional limitations by efficiently screening peptides, eliminating ineffective candidates, and continuously refining predictions using real-world data. This innovation is particularly significant for developing targeted therapies for cancers and infectious diseases, while considering diverse genetic factors like age, sex, race, and ethnicity.
Tevogen Bio Holdings (Nasdaq: TVGN) ha ottenuto una pubblicazione di brevetto internazionale da parte di WIPO per la sua tecnologia AI che prevede peptidi immunologicamente attivi. Il brevetto (WO 2025/129197) riguarda la tecnologia di machine learning di Tevogen.AI, supportata da Microsoft e Databricks, progettata per identificare peptidi con forti interazioni con il sistema immunitario.
Questa tecnologia mira a superare le limitazioni tradizionali, selezionando efficacemente i peptidi, eliminando i candidati inefficaci e affinando continuamente le previsioni utilizzando dati reali. Questa innovazione 猫 particolarmente importante per lo sviluppo di terapie mirate per cancro e malattie infettive, tenendo conto di fattori genetici diversi come et脿, sesso, razza ed etnia.
Tevogen Bio Holdings (Nasdaq: TVGN) ha recibido una publicaci贸n internacional de patente por parte de la WIPO para su tecnolog铆a de IA que predice p茅ptidos inmunol贸gicamente activos. La patente (WO 2025/129197) cubre la tecnolog铆a de aprendizaje autom谩tico de Tevogen.AI, impulsada por Microsoft y Databricks, dise帽ada para identificar p茅ptidos con fuertes interacciones con el sistema inmunol贸gico.
La tecnolog铆a busca superar las limitaciones tradicionales mediante la selecci贸n eficiente de p茅ptidos, eliminando candidatos ineficaces y refinando continuamente las predicciones con datos del mundo real. Esta innovaci贸n es especialmente significativa para el desarrollo de terapias dirigidas contra c谩nceres y enfermedades infecciosas, considerando factores gen茅ticos diversos como edad, sexo, raza y etnia.
Tevogen Bio Holdings (雮橃姢雼�: TVGN)鞚� 氅挫棴頃欖爜鞙茧 頇滌劚頇旊悳 韼╉儉鞚措摐毳� 鞓堨浮頃橂姅 AI 旮办垹鞐� 雽�頃� WIPO搿滊秬韯� 甑牅 韸鬼棃 瓿惦炒毳� 氚涭晿鞀惦媹雼�. 鞚� 韸鬼棃(WO 2025/129197)電� Microsoft鞕� Databricks臧� 歆�鞗愴晿電� Tevogen.AI鞚� 毹胳嫚霟嫕 旮办垹鞚� 韽暔頃橂┌, 氅挫棴 觳搓硠鞕� 臧曤牓頃橁矊 靸來樃鞛戩毄頃橂姅 韼╉儉鞚措摐毳� 鞁濍硠頃橂弰搿� 靹り硠霅橃棃鞀惦媹雼�.
鞚� 旮办垹鞚� 鞝勴喌鞝侅澑 頃滉硠毳� 攴闺车頃橁赴 鞙勴暣 韼╉儉鞚措摐毳� 須湪鞝侅溂搿� 靹犽硠頃橁碃, 須臣 鞐嗠姅 頉勲炒毳� 鞝滉卑頃橂┌, 鞁れ牅 雿办澊韯半ゼ 頇滌毄頃� 鞓堨浮鞚� 歆�靻嶌爜鞙茧 臧滌劆頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 鞚� 順侅嫚鞚� 鞎� 氚� 臧愳椉靹� 歆堩櫂鞐� 雽�頃� 毵烄钉順� 旃橂氩� 臧滊皽鞐� 韸鬼瀳 欷戩殧頃橂┌, 鞐半牴, 靹彪硠, 鞚胳 氚� 氙检”瓿� 臧欖潃 雼れ枒頃� 鞙犾爠鞝� 鞖旍澑鞚� 瓿犽牑頃╇媹雼�.
Tevogen Bio Holdings (Nasdaq : TVGN) a re莽u une publication de brevet international de la part de l鈥橭MPI pour sa technologie d鈥橧A qui pr茅dit les peptides immunologiquement actifs. Le brevet (WO 2025/129197) couvre la technologie d鈥檃pprentissage automatique de Tevogen.AI, propuls茅e par Microsoft et Databricks, con莽ue pour identifier les peptides ayant de fortes interactions avec le syst猫me immunitaire.
Cette technologie vise 脿 d茅passer les limites traditionnelles en s茅lectionnant efficacement les peptides, en 茅liminant les candidats inefficaces et en affinant continuellement les pr茅dictions 脿 l鈥檃ide de donn茅es r茅elles. Cette innovation est particuli猫rement importante pour le d茅veloppement de th茅rapies cibl茅es contre les cancers et les maladies infectieuses, en tenant compte de divers facteurs g茅n茅tiques tels que l鈥櫭e, le sexe, la race et l鈥檈thnie.
Tevogen Bio Holdings (Nasdaq: TVGN) hat von der WIPO eine internationale Patentschrift f眉r seine KI-Technologie erhalten, die immunologisch aktive Peptide vorhersagt. Das Patent (WO 2025/129197) umfasst die Machine-Learning-Technologie von Tevogen.AI, unterst眉tzt von Microsoft und Databricks, die darauf ausgelegt ist, Peptide mit starken Wechselwirkungen zum Immunsystem zu identifizieren.
Die Technologie zielt darauf ab, traditionelle Einschr盲nkungen zu 眉berwinden, indem sie Peptide effizient screenet, unwirksame Kandidaten eliminiert und Vorhersagen kontinuierlich mithilfe von AG真人官方welt-Daten verfeinert. Diese Innovation ist besonders bedeutend f眉r die Entwicklung gezielter Therapien gegen Krebs und Infektionskrankheiten, wobei verschiedene genetische Faktoren wie Alter, Geschlecht, Rasse und Ethnie ber眉cksichtigt werden.
- International patent publication received for AI-powered peptide prediction technology
- Technology addresses limitations in traditional peptide identification methods
- Partnership with major tech companies Microsoft and Databricks
- Potential to accelerate drug development and reduce costs
- System considers human genetic diversity factors in predictions
- Early-stage technology with no proven commercial success yet
- Company has limited operating history
- Additional capital may be needed to execute business plan
- Faces significant regulatory and development risks
Insights
Tevogen's AI patent publication marks a strategic IP milestone, potentially accelerating immunotherapy development while reducing costs.
Tevogen's international patent publication represents a significant intellectual property milestone for their AI-driven drug discovery platform. The technology addresses a critical bottleneck in immunotherapy development - identifying peptides that effectively interact with the immune system. What makes this approach particularly valuable is its ability to account for human genetic diversity factors like age, sex, race, and ethnicity that traditional methods often overlook.
The patent covers three key technical capabilities that differentiate Tevogen's platform: 1) efficient screening and ranking of peptides based on immunological activity, 2) elimination of likely ineffective peptides due to self-tolerance or human genome overlap, and 3) continuous refinement through machine learning. These capabilities directly address fundamental challenges in peptide-based therapy development.
This patent publication strengthens Tevogen's competitive position in the rapidly evolving immunotherapy space. By leveraging partnerships with technology leaders Microsoft and Databricks, Tevogen is positioning its AI platform to potentially reduce development timelines and costs for personalized T cell therapies - addressing major commercial barriers in this therapeutic category.
The strategic significance extends beyond this single patent, as it signals Tevogen's commitment to building a robust IP portfolio around AI-driven drug discovery. For a publicly-traded biotech company, such patent publications are valuable assets that can drive partnership opportunities and enhance the company's valuation proposition, especially in the current environment where AI applications in drug discovery command significant premium.
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- (鈥淭evogen Bio Holdings Inc.鈥� or 鈥淐ompany鈥�) (Nasdaq: ) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."
This patent covers technology developed by Tevogen.AI that leverages machine learning algorithms, powered by Microsoft (Nasdaq: ) and Databricks intended to rapidly and accurately identify peptides with strong immune system interactions. Identifying these peptides is critical in developing targeted therapies for a variety of diseases, including cancers and infectious diseases.
Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity. Tevogen.AI鈥檚 proprietary approach may overcome these challenges by:
- Efficiently screening and ranking potential peptides based on their immunological activity.
- Eliminating peptides likely to be ineffective due to self-tolerance or human genome overlap.
- Continuously refining predictions using real-world data to train and enhance machine learning models.
鈥淚鈥檓 pleased with Tevogen.AI鈥檚 continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,鈥� said Dr. Ryan Saadi, Founder and CEO of Tevogen. 鈥淟everaging AI to accelerate discovery, shorten development timelines, and reduce costs is essential to our mission of delivering commercially attractive, economically viable, and cost-effective personalized T cell therapies.鈥�
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen鈥檚 plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen鈥檚 development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 鈥渕ay,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥済oal,鈥� 鈥渙pportunity,鈥� 鈥減roject,鈥� 鈥渂elieve,鈥� 鈥渇uture,鈥� and similar words and expressions or their opposites. These statements are based on management鈥檚 expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company鈥檚 control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen鈥檚 commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen鈥檚 business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen鈥檚 limited operating history; and those factors discussed or incorporated by reference in Tevogen鈥檚 Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
FAQ
What is the significance of Tevogen's new AI patent publication?
How does Tevogen's AI technology improve peptide identification?
Who are Tevogen's technology partners for this AI system?
What are the main challenges facing Tevogen's AI technology implementation?
How does Tevogen's AI technology account for patient diversity?
